Evidence map›Paper›PMID 39065565›Full record

ReviewPharmaceutics2024

Gene Therapy with Chitosan Nanoparticles: Modern Formulation Strategies for Enhancing Cancer Cell Transfection.

Varvara Antoniou, Elena A Mourelatou, Eleftheria Galatou, Konstantinos Avgoustakis, Sophia Hatziantoniou

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Varvara AntoniouPharmacy Program, Department of Health Sciences, School of Life and Health Sciences, University of Nicosia, Nicosia 2417, Cyprus.
Elena A MourelatouPharmacy Program, Department of Health Sciences, School of Life and Health Sciences, University of Nicosia, Nicosia 2417, Cyprus.
Eleftheria GalatouPharmacy Program, Department of Health Sciences, School of Life and Health Sciences, University of Nicosia, Nicosia 2417, Cyprus.ORCID 0000-0002-5395-7573
Konstantinos AvgoustakisLaboratory of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, University of Patras, 26 504 Rion, Greece.
Sophia HatziantoniouLaboratory of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, University of Patras, 26 504 Rion, Greece.ORCID 0000-0002-5877-9091

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gene therapy involves the introduction of exogenous genetic material into host tissues to modify gene expression or cellular properties for therapeutic purposes. Initially developed to address genetic disorders, gene therapy has expanded to encompass a wide range of conditions, notably cancer. Effective delivery of nucleic acids into target cells relies on carriers, with non-viral systems gaining prominence due to their enhanced safety profile compared to viral vectors. Chitosan, a biopolymer, is frequently utilized to fabricate nanoparticles for various biomedical applications, particularly nucleic acid delivery, with recent emphasis on targeting cancer cells. Chitosan's positively charged amino groups enable the formation of stable nanocomplexes with nucleic acids and facilitate interaction with cell membranes, thereby promoting cellular uptake. Despite these advantages, chitosan-based nanoparticles face challenges such as poor solubility at physiological pH, non-specificity for cancer cells, and inefficient endosomal escape, limiting their transfection efficiency. To address these limitations, researchers have focused on enhancing the functionality of chitosan nanoparticles. Strategies include improving stability, enhancing targeting specificity, increasing cellular uptake efficiency, and promoting endosomal escape. This review critically evaluates recent formulation approaches within these categories, aiming to provide insights into advancing chitosan-based gene delivery systems for improved efficacy, particularly in cancer therapy.

Indexed as

cancer cell transfectioncancer gene therapychitosanchitosan nanoparticlesgene therapy

Identifiers

PMID39065565
PMCPMC11280172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.